At a recent forum in Seoul, an executive of Hanmi Pharmaceuticals, whose novel neutropenia drug has just received a US green light, shares why it is crucial to create "blue oceans" through global innovative drug development and how the Korean firm plans to challenge these markets.

Ahead of advisory committee review, agency cites poziotinib’s marginal anti-tumor activity, high rates of toxicity, and lack of dose optimization. Company seeks accelerated approval but was given standard review.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.